Use of progestogens as an adjuvant to surgery in the treatment of stage I adenocarcinoma of the uterine corpus.
Fifty-nine patients with proven stage I adenocarcinoma of the uterine corpus were treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, followed by gestronal hexanoate intramuscularly for 3 months and then medroxyprogesterone acetate orally for a prolonged period. In the 7-year period of study, there were no vaginal recurrences, but one patient suffered a recurrence in the inguinal lymph nodes and pelvis. Undesirable side effects did not occur. These results compare favourably with other reported studies in which surgery and radiotherapy were used.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D002369:Castration; D005260:Female; D005866:Gestonorone Caproate / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D011184:Postoperative Period; D012008:Recurrence; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D005866:Gestonorone Caproate